Gregory K. Palm
Director/Board Member bij Olatec Therapeutics LLC
Profiel
Gregory K.
Palm is currently a Director at Olatec Therapeutics LLC since 2021.
Previously, he worked as Secretary, Executive VP & General Counsel at The Goldman Sachs Group, Inc. from 2011 to 2018.
He completed his undergraduate degree at Massachusetts Institute of Technology and his graduate and MBA degrees at Harvard Business School.
Actieve functies van Gregory K. Palm
| Bedrijven | Functie | Begin |
|---|---|---|
Olatec Therapeutics LLC
 Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Director/Board Member | 29-07-2021 |
Eerdere bekende functies van Gregory K. Palm
| Bedrijven | Functie | Einde |
|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. | General Counsel | - |
Opleiding van Gregory K. Palm
| Massachusetts Institute of Technology | Undergraduate Degree |
| Harvard Business School | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| THE GOLDMAN SACHS GROUP, INC. | Finance |
| Bedrijven in privébezit | 1 |
|---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Health Technology |
